Cdt Equity(NASDAQ) CDT

CDT Equity helps bring new medicines to market by developing drugs that larger companies have set aside.

Its work supports patients with autoimmune diseases and infertility.

The company uses artificial intelligence and chemistry to improve drug properties for better treatment options.

What’s in the Medicine Cabinet? (Products and Services)

• Clinical Asset Development: CDT identifies and advances early-stage drugs for autoimmune, oncology, and infertility conditions.
• AI-Powered Asset Selection: Uses artificial intelligence to find promising drug candidates for further development.
• Solid-Form Chemistry: Applies co-crystallization to improve drug stability and extend patent life.
• Animal Health Evaluation: Tests select assets for use in animal health markets.
• Diagnostic Dashboards: Offers tools for monitoring clinical trials and analyzing patent landscapes.

Growth Spurts and Strategic Moves

• 2024: Licensed key drug assets from AstraZeneca for autoimmune and infertility research.
• 2024: Signed technology partnership with Sarborg for AI-driven drug selection.
• 2025: Expanded AI analysis and asset evaluation with Sarborg.
• 2025: Entered joint development with Manoira to explore animal health applications.
• 2024–2025: Addressed Nasdaq listing compliance and resolved related issues.

Why CDT Equity Stands Out (Without the Lab Coat)

CDT Equity operates with a small team and outsources research to keep costs low. Its business model focuses on early-stage drug development, avoiding expensive late-stage trials. The company leverages partnerships and technology to identify and enhance overlooked drug candidates.

Five Things You Need to Know

• Revenue was $698 million in QQ3 2025, up 6.6% from QQ3 2024.
• Net income reached $76 million in QQ3 2025, reversing a loss last year.
• Cash flow from operations was $105 million in QQ3 2025, up from negative $2 million.
• Research and development expenses rose 1,714% year-over-year in the first half of 2025.
• As of June 2025, the company had $3.3 million in cash and a $39.9 million accumulated deficit.

Bottom Line

CDT Equity has evolved by focusing on early-stage drug development and leveraging partnerships. Its adaptable model and technology-driven approach help it navigate a challenging biotechnology landscape.